Corautus Genetics, Inc.

Phase IIb GENASIS clinical trial receives recommendation to proceed

Published in Drug Law Weekly, May 3rd, 2005

Corautus Genetics, Inc., (VEGF) announced that as the result of its scheduled interim safety analysis, the independent data monitoring committee (DMC) recommended the continuation of GENASIS (Genetic Angiogenic Stimulation Investigational Study), Corautus' phase IIb clinical trial to evaluate the safety and efficacy of Vascular Endothelial Growth Factor-2 (VEGF-2) for the treatment of patients with severe angina.

The planned interim safety analysis was conducted after the first 54 patients were treated in the trial. The DMC is comprised of independent physicians and a statistician and was established to monitor the safety data from the trial. Based upon their review of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2005-05-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry